ReviewExpert opinion on therapeutic targets2012
Targeting angiogenesis for the treatment of prostate cancer.
Review in Expert opinion on therapeutic targets, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 32 citations in OpenAlex.
- Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer.BJU international · 2013Trial
- Membrane-derived particles shed by PSMA-positive cells function as pro-angiogenic stimuli in tumors.Journal of controlled release : official journal of the Controlled Release Society · 2023Article
- The αvβ6 integrin in cancer cell-derived small extracellular vesicles enhances angiogenesis.Journal of extracellular vesicles · 2020Article
- Different roles of myofibroblasts in the tumorigenesis of nonsmall cell lung cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Histone demethylase JMJD2A drives prostate tumorigenesis through transcription factor ETV1.The Journal of clinical investigation · 2016Article
- Adiponectin inhibits VEGF-A in prostate cancer cells.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Differential sensitivity of prostate tumor derived endothelial cells to sorafenib and sunitinib.BMC cancer · 2014Article
- Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases.Science translational medicine · 2014Article
- Monoamine oxidase A mediates prostate tumorigenesis and cancer metastasis.The Journal of clinical investigation · 2014Article
- Abundant in vitro expression of the oncofetal ED-B-containing fibronectin translates into selective pharmacodelivery of (131)I-L19SIP in a prostate cancer patient.Journal of cancer research and clinical oncology · 2014Article
- Scl gene construction, expression and effect on hemangioma.Molecular biology reports · 2013Article
- Antiproliferative and apoptotic effects of a specific antiprostate stem cell single chain antibody on human prostate cancer cells.Journal of oncology · 2013Article
- Exploring the role of anti-angiogenic therapies in prostate cancer: results from the phase 3 trial of sunitinib.Asian journal of andrologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
introductionWhile multiple therapies exist that prolong the lives of men with advanced prostate cancer, none are curative. This had led to a search to uncover novel targets for prostate cancer therapy, distinct from those of traditional hormonal approaches, chemotherapies, immunotherapies and bone-targeting approaches. The process of tumor angiogenesis is one target that is being exploited for therapeutic gain. AREAS COVERED: The most promising anti-angiogenic approaches for treatment of prostate cancer, focusing on clinical development of selected agents. These include VEGF-directed therapies, tyrosine kinase inhibitors, tumor-vascular disrupting agents, immunomodulatory drugs and miscellaneous anti-angiogenic agents. While none of these drugs have yet entered the market for the treatment of prostate cancer, several are now being tested in Phase III registrational trials. EXPERT OPINION: The development of anti-angiogenic agents for prostate cancer has met with several challenges. This includes discordance between traditional prostate-specific antigen responses and clinical responses, which have clouded clinical trial design and interpretation, potential inadequate exposure to anti-angiogenic therapies with premature discontinuation of study drugs and the development of resistance to anti-angiogenic monotherapies. These barriers will hopefully be overcome with the advent of more potent agents, the use of dual angiogenesis inhibition and the design of more informative clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.